A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension

Trial Profile

A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms PARAMETER
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Aug 2017 Planned locations also included Brazil as per European Clinical Trials Database.
    • 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top